Journal of Traditional Chinese Medicine ›› 2025, Vol. 45 ›› Issue (3): 633-638.DOI: 10.19852/j.cnki.jtcm.2025.03.016
Previous Articles Next Articles
Clinical effect of Shugan Jieyu San (疏肝解郁散) for improving liver function and alleviating depression in patients with triple negative breast cancer
ZHANG Yang1(
), LYU Wang1, XU Xin1, LI Jie2, HU Shengli3, WANG Ying1
- 1 Department of Traditional Chinese Medicine, Cangzh ou Central Hospital, Cangzhou 061001, China
2 Thyroid and Breast Surgery Department, Cangzhou Central Hospital, Cangzhou 061001, China
3 Information construction office, Cangzhou Central Hospital, Cangzhou 061001, China
-
Received:2024-02-22Accepted:2024-08-20Online:2025-06-15Published:2025-05-21 -
Contact:ZHANG Yang, Department of Traditional Chinese Medicine, Cangzhou Central Hospital, Cangzhou 061001, China. yangzhang5605@126.com,Telephone: +86-15100786853
Cite this article
ZHANG Yang, LYU Wang, XU Xin, LI Jie, HU Shengli, WANG Ying. Clinical effect of Shugan Jieyu San (疏肝解郁散) for improving liver function and alleviating depression in patients with triple negative breast cancer[J]. Journal of Traditional Chinese Medicine, 2025, 45(3): 633-638.
share this article
Figure 1 Research framework of the study This figure illustrates the research framework employed in the current study. HAMD: Hamilton Depression Rating Scale; KPS: Karnofsky Performance Status; IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; DA: dopamine; 5-HT: serotonin.
Figure 1 Research framework of the study This figure illustrates the research framework employed in the current study. HAMD: Hamilton Depression Rating Scale; KPS: Karnofsky Performance Status; IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; DA: dopamine; 5-HT: serotonin.
Table 1 Demographic and clinical characteristics of study participants [n (%)]
| Feature | Control group (n = 30) | Observation group (n = 30) | P value | |
|---|---|---|---|---|
| Age (years) | < 50 | 12 (40.0) | 14 (46.7) | 0.795 |
| ≥ 50 | 18 (60.0) | 16 (53.3) | ||
| Family history of breast cancer | Yes | 1 (3.3) | 0 (0.0) | 0.999 |
| No | 29 (96.7) | 30 (100.0) | ||
| Menstrual state | Post-menopause | 13 (43.3) | 10 (33.3) | 0.596 |
| Pre-menopause | 17 (56.7) | 20 (66.7) | ||
| Pathological type | Invasive ductal carcinoma | 23 (76.7) | 21 (70.0) | 0.475 |
| Invasive lobular carcinoma | 5 (16.7) | 4 (13.3) | ||
| Medullary carcinoma | 2 (6.6) | 5 (16.7) | ||
| Histological grade | Ⅰ | 10 (33.3) | 7 (23.3) | 0.691 |
| Ⅱ | 13 (43.3) | 15 (50.0) | ||
| Ⅲ | 7 (23.3) | 8 (26.7) | ||
| Lymph node metastasis | Positive | 4 (13.3) | 6 (20.0) | 0.731 |
| Negative | 26 (86.7) | 24 (80.0) | ||
| Tumor size (cm) | ≤ 2 | 10 (33.3) | 8 (26.7) | 0.779 |
| > 2 | 20 (66.7) | 22 (73.3) | ||
| Education status | Junior high school and below | 8 (26.7) | 9 (30.0) | 0.855 |
| Senior high school | 19 (63.3) | 17 (56.7) | ||
| College and above | 3 (10.0) | 4 (13.3) | ||
Table 1 Demographic and clinical characteristics of study participants [n (%)]
| Feature | Control group (n = 30) | Observation group (n = 30) | P value | |
|---|---|---|---|---|
| Age (years) | < 50 | 12 (40.0) | 14 (46.7) | 0.795 |
| ≥ 50 | 18 (60.0) | 16 (53.3) | ||
| Family history of breast cancer | Yes | 1 (3.3) | 0 (0.0) | 0.999 |
| No | 29 (96.7) | 30 (100.0) | ||
| Menstrual state | Post-menopause | 13 (43.3) | 10 (33.3) | 0.596 |
| Pre-menopause | 17 (56.7) | 20 (66.7) | ||
| Pathological type | Invasive ductal carcinoma | 23 (76.7) | 21 (70.0) | 0.475 |
| Invasive lobular carcinoma | 5 (16.7) | 4 (13.3) | ||
| Medullary carcinoma | 2 (6.6) | 5 (16.7) | ||
| Histological grade | Ⅰ | 10 (33.3) | 7 (23.3) | 0.691 |
| Ⅱ | 13 (43.3) | 15 (50.0) | ||
| Ⅲ | 7 (23.3) | 8 (26.7) | ||
| Lymph node metastasis | Positive | 4 (13.3) | 6 (20.0) | 0.731 |
| Negative | 26 (86.7) | 24 (80.0) | ||
| Tumor size (cm) | ≤ 2 | 10 (33.3) | 8 (26.7) | 0.779 |
| > 2 | 20 (66.7) | 22 (73.3) | ||
| Education status | Junior high school and below | 8 (26.7) | 9 (30.0) | 0.855 |
| Senior high school | 19 (63.3) | 17 (56.7) | ||
| College and above | 3 (10.0) | 4 (13.3) | ||
Figure 2 Comparisons of HAMD and KPS scores before and after 4 and 8 weeks of treatment A: HAMD scores; B: KPS scores. The control group received duloxetine in addition to routine tumor treatment protocols. The dosage consisted of two tablets per day, administered orally, with one tablet in the morning and one at noon. The observation group received a self-formulated Shugan Jieyu San in addition to the treatment provided to the control group. HAMD: Hamilton Depression Rating Scale; KPS: Karnofsky Performance Status. Two-way analysis of variance analysis followed with a Tukey's multiple comparisons test. Data were shown with box plot (n = 30). aP < 0.05 compared to Control at the same time point; bP < 0.05 compared to the time of before treatment in the same group.
Figure 2 Comparisons of HAMD and KPS scores before and after 4 and 8 weeks of treatment A: HAMD scores; B: KPS scores. The control group received duloxetine in addition to routine tumor treatment protocols. The dosage consisted of two tablets per day, administered orally, with one tablet in the morning and one at noon. The observation group received a self-formulated Shugan Jieyu San in addition to the treatment provided to the control group. HAMD: Hamilton Depression Rating Scale; KPS: Karnofsky Performance Status. Two-way analysis of variance analysis followed with a Tukey's multiple comparisons test. Data were shown with box plot (n = 30). aP < 0.05 compared to Control at the same time point; bP < 0.05 compared to the time of before treatment in the same group.
Figure 3 Comparisons of serum IL-6 and TNF-α levels before and after 8 weeks of treatment A: serum IL-6 levels; B: TNF-α levels. The control group received duloxetine in addition to routine tumor treatment protocols. The dosage consisted of two tablets per day, administered orally, with one tablet in the morning and one at noon. The observation group received a self-formulated Shugan Jieyu San in addition to the treatment provided to the control group. IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha. Two-way analysis of variance analysis followed with a Tukey's multiple comparisons test. Data were shown with box plot (n = 30). aP < 0.05 compared to the time of before treatment in the same group; bP < 0.05 compared to Control at the same time point.
Figure 3 Comparisons of serum IL-6 and TNF-α levels before and after 8 weeks of treatment A: serum IL-6 levels; B: TNF-α levels. The control group received duloxetine in addition to routine tumor treatment protocols. The dosage consisted of two tablets per day, administered orally, with one tablet in the morning and one at noon. The observation group received a self-formulated Shugan Jieyu San in addition to the treatment provided to the control group. IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha. Two-way analysis of variance analysis followed with a Tukey's multiple comparisons test. Data were shown with box plot (n = 30). aP < 0.05 compared to the time of before treatment in the same group; bP < 0.05 compared to Control at the same time point.
Figure 4 Comparisons of serum DA and 5-HT levels before and after 8 weeks of treatment A: serum DA levels; B: 5-HT levels. The control group received duloxetine in addition to routine tumor treatment protocols. The dosage consisted of two tablets per day, administered orally, with one tablet in the morning and one at noon. The observation group received a self-formulated Shugan Jieyu San in addition to the treatment provided to the control group. DA: dopamine; 5-HT: serotonin. Two-way analysis of variance analysis followed with a Tukey's multiple comparisons test. Data were shown with box plot (n = 30). aP < 0.05 compared to Control at the same time point; bP < 0.05 compared to the time of before treatment in the same group.
Figure 4 Comparisons of serum DA and 5-HT levels before and after 8 weeks of treatment A: serum DA levels; B: 5-HT levels. The control group received duloxetine in addition to routine tumor treatment protocols. The dosage consisted of two tablets per day, administered orally, with one tablet in the morning and one at noon. The observation group received a self-formulated Shugan Jieyu San in addition to the treatment provided to the control group. DA: dopamine; 5-HT: serotonin. Two-way analysis of variance analysis followed with a Tukey's multiple comparisons test. Data were shown with box plot (n = 30). aP < 0.05 compared to Control at the same time point; bP < 0.05 compared to the time of before treatment in the same group.
| 1. | Scott LC, Mobley LR, Kuo TM, et al. Update on triple-negative breast cancer disparities for the United States: a population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer 2019; 125: 3412-17. |
| 2. |
Park J, Jonas S, Bataillon G, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol 2019; 30: 1941-9.
DOI PMID |
| 3. |
Salek R, Dehghani M, Mohajeri SA, et al. Amelioration of anxiety, depression, and chemotherapy related toxicity after crocin administration during chemotherapy of breast cancer: a double blind, randomized clinical trial. Phytother Res 2021; 35: 5143-53.
DOI PMID |
| 4. | Shen A, Qiang W, Wang Y, et al. Quality of life among breast cancer survivors with triple negative breast cancer--role of hope, self-efficacy and social support. Eur J Oncol Nurs 2020; 46: 101771. |
| 5. |
Hong JS, Tian J. Prevalence of anxiety and depression and their risk factors in Chinese cancer patients. Support Care Cancer 2014; 22: 453-9.
DOI PMID |
| 6. | Stapel B, Melzer C, von der Ohe J, et al. Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines. Sci Rep 2021; 11: 1-14. |
| 7. | Bates N, Bello JK, Osazuwa-Peters N, et al. Depression and long-term prescription opioid use and opioid use disorder: implications for pain management in cancer. Curr Treat Options Oncol 2022; 23: 348-58. |
| 8. |
Abdel Karim NF, Hassan R, Siddiqi NI, et al. Impact of tricyclic antidepressants, selective serotonin reuptake inhibitors, and other antidepressants on overall survival of patients with advanced lung cancer from 2004 to 2014: University of Cincinnati experience. J Int Med Res 2019; 47: 6016-26.
DOI PMID |
| 9. | Strazzanti A, Martorana F, Intagliata E, et al. Implications of antidepressants use in breast cancer: a brief review. Surg Gastroenterol 2020; 25: 229-35. |
| 10. | Liu YC, Chen VCH, Lu ML, et al. The association between selective serotonin reuptake inhibitors (SSRIs) use and the risk of bladder cancer: a nationwide population-based cohort study. Cancers (Basel) 2020; 12: 1184. |
| 11. |
Li C, Huang J, Cheng YC, et al. Traditional Chinese Medicine in depression treatment: from molecules to systems. Front Pharmacol 2020; 11: 586.
DOI PMID |
| 12. | Chen TS, Chen PS. The liver in Traditional Chinese Medicine. J Gastroenterol Hepatol 1998; 13: 437-42. |
| 13. |
Huang X, Liu X, Yu Y. Depression and chronic liver diseases: are there shared underlying mechanisms? Front Mol Neurosci 2017; 10: 134.
DOI PMID |
| 14. |
Labenz C, Huber Y, Michel M, et al. Nonalcoholic fatty liver disease increases the risk of anxiety and depression. Hepatol Commun 2020; 4: 1293-301.
DOI PMID |
| 15. | Psychiatry Branch of Chinese Medical Association. CCMD-3 classification and diagnostic criteria of mental disorders in China Jinan: Shandong Science and Technology Press, 2001: 66-82. |
| 16. | Guidelines Formulation Group of the 2019 Breast Cancer Diagnosis and Treatment Guidelines of the Chinese Society of Clinical Oncology (CSCO). 2019 CSCO breast cancer diagnosis and treatment guidelines. Beijing: People's Medical Publishing House, 2019: 1-120. |
| 17. |
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.
DOI PMID |
| 18. | Chow EPY. Traditional Chinese Medicine: a holistic system. Alternative medicines. London: Routledge; 2022: 114-37. |
| 19. | Xiang Y, Guo Z, Zhu P, et al. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med 2019; 8: 1958-75. |
| 20. | Ye H, Ji M, Wang C, et al. Integrated functional neuroimaging, monoamine neurotransmitters, and behavioral score on depressive tendency in intensive care unit medical staffs induced by sleep deprivation after night shift work. Front Psychiatry 2022; 13: 848709. |
| 21. | Frappaz D, Bonneville-Levard A, Ricard D, et al. Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias. Support Care Cancer 2021; 29: 1883-91. |
| 22. |
He M, Luo Y, Chen L, et al. Shashen maidong decoction: the effect of TNF-α and IL-6 on lung cancer cachexia based on cancer toxicity theory. Am J Transl Res 2021; 13: 6752.
PMID |
| 23. | Chen YJ, Wu JY, Leung WC, et al. An herbal formula inhibits STAT3 signaling and attenuates bone erosion in collagen-induced arthritis rats. Phytomedicine 2020; 76: 153254. |
| 24. | Zhang K, Yang J, Wu C. Antidepressant-like effects and mechanisms of the herbal formula Xiaochaihutang in depression. The neuroscience of depression. Amsterdam: Elsevier; 2021: 519-28. |
| 25. | Gori P, Raval M, Patel S, et al. Role of medicinal plants in combating anti-depressant induced male infertility. Curr Tradit Med 2022; 8: 60-76. |
| [1] | LI Weijia, LU Jing, MA Chao, LIU Mengmeng, PEI Ke, CHEN Hongyan, LIN Zhe, LYU Guangfu. Hamayou (Oviductus Ranae) protein hydrolysate ameliorates depression by regulating the mitogen-activated protein kinase pathway [J]. Journal of Traditional Chinese Medicine, 2025, 45(3): 493-507. |
| [2] | LI Yongfeng, CHEN Xinyi, REN Wei, QIAO Haifa. Electroacupuncture stimulation of auricular concha region improves loss of control over stress induced depression-like behavior by modulating 5-hydroxytryptamine 1A receptor [J]. Journal of Traditional Chinese Medicine, 2025, 45(2): 326-334. |
| [3] | LI Yajing, WANG Baoying, SHAO Wenxue, LU Shuaifei, SU Pan, BAI Ming, XU Erping, LI Yucheng. Quantitative proteomic analysis of the brain reveals the potential antidepressant mechanism of Jiawei Danzhi Xiaoyao San (加味丹栀逍遥散) in a chronic unpredictable mild stress mouse model of depression [J]. Journal of Traditional Chinese Medicine, 2025, 45(1): 22-31. |
| [4] | Faiq Amin, Saara Ahmad, Muhammad Wasim, Asra Khan, Fazal Manzoor Arain, Zehra Batool, Saiqa Tabassum, Saima Khaliq, Noreen Samad, Saida Haider. Antidepressive and anxiolytic effects of a combination of Saffron and Chamomile in rats and their relationship with serotonin using in vivo methods [J]. Journal of Traditional Chinese Medicine, 2025, 45(1): 49-56. |
| [5] | LIU Tongtong, ZHANG Xi, YANG Hui, LIN Xiaoyuan, LIU Jian, ZHANG Xiuli, GUO Dongwei, ZHAO Hongqing, ZOU Manshu, LEI Chang, LONG Hongping, LUO Yan, XIANG Yun, GE Jinwen, WANG Yuhong, MENG Pan. Luteolin promotes neuronogenesis in hippocampus of chronic unpredictable mild stress rats and primary hippocampus of fetal rats [J]. Journal of Traditional Chinese Medicine, 2024, 44(4): 670-679. |
| [6] | LI Ruibai, CHEN Ke, MA Wei, ZHANG Yayue, HOU Li, CHEN Xinyi. Hemostatic mechanism of Jianpi Yiqi Shexue decoction (健脾益气摄血方) in treatment of immune thrombocytopenia [J]. Journal of Traditional Chinese Medicine, 2024, 44(3): 537-544. |
| [7] | WANG Yaqi, ZHAO Weibo, WANG Yixing, ZHAO Haihong, ZHOU Yaoyao, YAN Yun, WU Taotao, LUO Bin, WANG Ji. Traditional Chinese Medicine constitution among patients with allergic rhinitis and its correlation with anxiety and depression [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1252-1258. |
| [8] | TANG Wenjuan, HU Yu, ZHU Man, DONG Mingzhi, LIU Tieming, SARWAR Ammar, ZHAN Yingzhuan, ZHANG Yanmin. Pingxiao capsule (平消胶囊) inhibits lung metastasis of triple-negative breast cancer and sensitizes breast cancer to radiotherapy [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 897-905. |
| [9] | CAO Wencong, LIAO Shaojun, ZHANG Yuanwen, ZHOU Li, LI Geng, OUYANG Wenwei, WEN Zehuai. Effectiveness and safety of Xuefu Zhuyu oral liquid (血府逐瘀口服液) on Qi-stagnation and blood-stasis pattern in patients with stable angina, tension-type headache and primary dysmenorrhea: rationale and design of a master protocol [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 815-823. |
| [10] | MA Fangfang, ZHANG Hewei, LI Bingxue, CHENG Peiyu, YU Mingwei, WANG Xiaomin. Acupuncture and moxibustion for malignant tumor patients with psychological symptoms of insomnia, anxiety and depression: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 441-456. |
| [11] | WU Haiyang, WANG Ying, HAN Wei, LI Huihui, JI Haisheng, LIU Xiuxiu. Protective effect of Tongdu Tiaoshen acupuncture combined with Xiaoxuming decoction (小续命汤) on dopaminergic neurons in Parkinson’s disease model [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 484-493. |
| [12] | FENG Min, JIA Ziming, WAN Ming, FAN Bolin, TANG Xiaoqiao, CHENG Wenhua, SUN Fanzhong. Effectiveness of Fuling (Poria) and its extracts against spleen deficiency in rats via tonifying spleen [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 501-506. |
| [13] | ZOU Xinshuang, SHI Lei, YIN Hailong, LI Haiping, WANG Mengheng, SONG Wanci, LUO Laichun, WU Hezhen, YANG Yanfang, ZAN Junfeng, LIU Yanwen, DAN Hanxiong, YIN Qiang, YOU Pengtao. Compound Gaoziban tablet (复方高滋斑片) alleviates depression via toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-kappa B pathway [J]. Journal of Traditional Chinese Medicine, 2022, 42(6): 956-964. |
| [14] | CHEN Limei, SUN Jifei, GUO Chunlei, LI Xiaojiao, WANG Zhi, Hong Yang, FANG Jiliang. Preliminary single-arm study of brain effects during transcutaneous auricular vagus nerve stimulation treatment of recurrent depression by resting-state functional magnetic resonance imaging [J]. Journal of Traditional Chinese Medicine, 2022, 42(5): 818-824. |
| [15] | ZHANG Zhaohua, LIU Rong, DU Nana, ZHU Xiangdong. Efficacy of Sishen Wan (四神丸) on dinitrobenzene sulfonic acid-induced ulcerative colitis and its effect on toll-like receptor 2/interleukin-1 receptor-associated kinase-4/nuclear factor-κB signal pathway [J]. Journal of Traditional Chinese Medicine, 2022, 42(4): 565-575. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
